Biogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals,...

Biogen has successfully completed its acquisition of Apellis Pharmaceuticals for $41 per share plus contingent value rights. The deal adds two commercialized products—EMPAVELI and SYFOVRE—which generated $689 million in net product revenue in 2025. The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and signif...

Biogen shares rose 1.06% to $193.40 despite the FDA extending its review of Leqembi Iqlik by three months to August 24, 2026. The company is also advancing its pipeline through the acquisition of Apellis Pharmaceuticals for $5.6 billion and benefiting from FDA approval of a new high-dose regimen for Spinraza. The stock has gained 63.29% over the ...

The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from maj...

Biogen has entered into an agreement with Alloy Therapeutics to accelerate the development of antisense therapies for multiple undisclosed indications. Alloy's AntiClastic ASO platform aims to improve the effectiveness of antisense therapeutics by targeting disease pathways at the RNA level. This partnership follows Alloy's January 2025 collabora...